

## ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Company name: VISION6

Website: Non

CEO name- Eugene De Juan

Category: **Medical Devices**

Session: **Restoring Vision: Where Biology Meets Engineering**

• *Executive Summary / Investment Rational: Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths*

FSV6 Ltd. developed the **Opira Accommodating IOL** to address the global cataract market. Using a ciliary-driven, fluid-filled silicone chamber, Opira restores continuous, youthful vision at all distances without optical compromises. This technology overcomes visual limitations inherent in current monofocal and multifocal lenses.

Managed by well-experienced physicians and engineers with extensive experience in developing ophthalmic devices.

FSV6 has validated safety and efficacy through preclinical and clinical.

Over 300 eyes implanted, with well-established safety and efficacy results.

• *Core Technology: What is the technology, its uniqueness, and its value proposition?*

### **Uniqueness of Technology**

The Opira AIOL is unique for its ciliary-driven shape-change mechanism. While traditional lenses are static, the Opira system uses the natural movement of the ciliary muscle to provide over 3 Diopters of accommodation. The Opira is positioned outside the capsular bag, unlike other accommodating AIOLs in development. This location ensures predictable, stable visual acuity over time.

### **Value Proposition**

The primary value of the Opira AIOL is the restoration of youthful, compromise-free vision at all distances—near, intermediate, and far.

- **Elimination of Spectacles:** Patients can see for all distances without the aid of glasses.
- **Superior Visual Quality:** The Opira AIOL provides high-quality, continuous focus without optical compromises, unlike multifocal IOLs, which cause glare, halos, and starbursts.

• *Product Profile/Pipeline: Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships.*

The Main product is an accommodative IOL for cataract patients, providing spectacle independence and advanced optics.

The U.S. IOL market is roughly USD 1.5 billion in 2024, and about USD 2.40 billion by 2030. While premium IOLs account for 20% of the market, it generates 60% of revenues.

Potential for collaborations with strategic partners.

• *Business Strategy: Briefly describe how the company will apply its core technology, generate short-term and long-term revenues.*

The company has been active for 12 years, developing 4 main product generations, all of which have been tested in clinical trials.

• *What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans*

Following successful clinical trials in South America, the next stage is preparation for FDA approval.